$KDCE
KID CASTLE EDUCATIONAL CORP Stock $kdce

$kdce Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223018079 Filed on May 18, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$380.9K	$1.039M
YoY Change	-63.33%
Cost Of Revenue	$60.10K	$308.4K
YoY Change	-80.51%
Gross Profit	$320.8K	$730.6K
YoY Change	-56.09%
Gross Profit Margin	84.22%	70.32%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$13.48K	$15.02K
YoY Change	-10.25%
% of Gross Profit	4.2%	2.06%
Operating Expenses	$38.64K	$135.0K
YoY Change	-71.38%
Operating Profit	$282.2K	$595.6K
YoY Change	-52.62%
Interest Expense	$335.00	$38.00
YoY Change	781.58%
% of Operating Profit	0.12%	0.01%
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	$282.2K	$599.3K
YoY Change	-52.91%
Net Earnings / Revenue	74.08%	57.68%
Basic Earnings Per Share	$0.01	$0.03
Diluted Earnings Per Share	$0.01
COMMON SHARES
Basic Shares Outstanding	22.32M shares	22.32M shares
Diluted Shares Outstanding	22.32M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$19.06K	$73.90K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$112.4K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$87.60K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.635M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$112.4K
Total Long-Term Assets	$3.635M
Total Assets	$3.748M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$2.400K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.400K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$467.6K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.400K
Total Long-Term Liabilities	$467.6K
Total Liabilities	$470.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$4.361M
YoY Change
Common Stock	$223.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.278M
YoY Change
Total Liabilities & Shareholders Equity	$3.748M
YoY Change

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$282.2K	$599.3K
YoY Change	-52.91%
Depreciation, Depletion And Amortization	$13.48K	$15.02K
YoY Change	-10.25%
Cash From Operating Activities	$328.0K	$608.9K
YoY Change	-46.14%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$99.99K	-$140.4K
YoY Change	-171.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$473.3K	-$995.7K
YoY Change	-52.46%
NET CHANGE
Cash From Operating Activities	$328.0K	$608.9K
Cash From Investing Activities	$99.99K	-$140.4K
Cash From Financing Activities	-$473.3K	-$995.7K
Net Change In Cash	-$45.38K	-$527.1K
YoY Change	-91.39%
FREE CASH FLOW
Cash From Operating Activities	$328.0K	$608.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001049011
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	KDCE	Line Of Credit Related Party Current LineOfCreditRelatedPartyCurrent		usd
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Financing Receivable After Allowance For Credit Loss Noncurrent Related And Nonrelated Party Status Extensible Enumeration FinancingReceivableAfterAllowanceForCreditLossNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Financing Receivable After Allowance For Credit Loss Noncurrent Related And Nonrelated Party Status Extensible Enumeration FinancingReceivableAfterAllowanceForCreditLossNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit		usd
CY2022Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit		usd
CY2023Q1	us-gaap	Investment Income Dividend InvestmentIncomeDividend		usd
CY2022Q1	us-gaap	Investment Income Dividend InvestmentIncomeDividend		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023Q1	us-gaap	Payments To Acquire Mining Assets PaymentsToAcquireMiningAssets		usd
CY2023Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2022Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2023Q1	KDCE	Repayments Of Brokerage Loan Margin Loan RepaymentsOfBrokerageLoanMarginLoan		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-56174
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	KID CASTLE EDUCATIONAL CORPORATION
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2549529
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	370 Amapola Ave
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200A
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Torrance
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90501
CY2023Q1	dei	City Area Code CityAreaCode	310
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	895-1839
CY2023Q1	dei	Security12g Title Security12gTitle	COMMON STOCK, $0.00001 PAR VALUE
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22324706	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19058	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64434	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	93349	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	143198	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	112407	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	207632	usd
CY2023Q1	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	102938	usd
CY2022Q4	us-gaap	Interest Receivable Noncurrent InterestReceivableNoncurrent	85375	usd
CY2023Q1	us-gaap	Investments Investments	30000	usd
CY2022Q4	us-gaap	Investments Investments	30000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87599	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	101081	usd
CY2023Q1	KDCE	Notes Receivable Entrepreneurship Development NotesReceivableEntrepreneurshipDevelopment	1738373	usd
CY2022Q4	KDCE	Notes Receivable Entrepreneurship Development NotesReceivableEntrepreneurshipDevelopment	1693420	usd
CY2023Q1	KDCE	Long Term Notes Receivable Related Parties LongTermNotesReceivableRelatedParties	1223000	usd
CY2022Q4	KDCE	Long Term Notes Receivable Related Parties LongTermNotesReceivableRelatedParties	747000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	453326	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	553314	usd
CY2023Q1	us-gaap	Assets Assets	3747643	usd
CY2022Q4	us-gaap	Assets Assets	3417822	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2400	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2400	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2400	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2400	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	467604	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	419979	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	467604	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	419979	usd
CY2023Q1	us-gaap	Liabilities Liabilities	470004	usd
CY2022Q4	us-gaap	Liabilities Liabilities	422379	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	10	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	10	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22324706	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22324706	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22324706	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22324706	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	223	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	223	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7638427	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7638427	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4361021	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4643217	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3277639	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2995443	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3747643	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3417822	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380932	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1038949	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	60100	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	308368	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	320832	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	730581	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25374	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	78256	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	12813	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	55925	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	114	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	798	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	335	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	38	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	38636	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	135017	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	282196	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	595565	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3700	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	282196	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	599264	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.0126
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.0268
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22324706	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22324706	shares
CY2008Q4	us-gaap	Stockholders Equity StockholdersEquity	1212819	usd
	KDCE	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	-1217127	usd
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-4308	usd
CY2019	KDCE	Stock Issued During Period Value Common Stock Issued Issuance StockIssuedDuringPeriodValueCommonStockIssuedIssuance	200	usd
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	9000	usd
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10	usd
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	181049	usd
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-149682	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	36269	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	49852	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-82980	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3141	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	9001	usd
CY2021	KDCE	Stock Issued During Period Value Acquisitions And Disposition StockIssuedDuringPeriodValueAcquisitionsAndDisposition	28025	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	2206953	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2229119	usd
CY2022	KDCE	Stock Issued During Period Value Dispositions Adjustment StockIssuedDuringPeriodValueDispositionsAdjustment	-1652	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	767976	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2995443	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	282196	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	282196	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3277639	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	282196	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	599264	usd
CY2023Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-49849	usd
CY2022Q1	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	5352	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-17563	usd
CY2023Q1	us-gaap	Depreciation Depreciation	13482	usd
CY2022Q1	us-gaap	Depreciation Depreciation	15021	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	327964	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	608933	usd
CY2022Q1	us-gaap	Payments To Acquire Mining Assets PaymentsToAcquireMiningAssets	34000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-99989	usd
CY2022Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	106374	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	99989	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140374	usd
CY2022Q1	KDCE	Repayments Of Brokerage Loan Margin Loan RepaymentsOfBrokerageLoanMarginLoan	23664	usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	47624	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	306750	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-44953	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	71216	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	476000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1350000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-473329	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-995698	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45376	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-527139	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64434	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	601042	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19058	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73903	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	336	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	38	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80D_eus-gaap--NatureOfOperations_zkiyzQHTvLOe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_822_zmuKCXkqWJ1">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The Company and Nature of Business</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Kid Castle Educational Corporation, a Delaware corporation, (“Kid Castle,” “the Company,” “We,” “KDCE,” “Us” or “Our’) operates and manages a portfolio of real estate properties, digital assets, and other in-demand properties. Kid Castle engages in rollup and consolidation of real estate, Biopharma and digital economy assets and operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Kid Castle was the result of a share exchange transaction, commonly referred to as a reverse merger, pursuant to which shareholders of an offshore operating company take control of a U.S. company that has no operations (commonly referred to as a shell company), and the offshore operating company becomes a subsidiary of the U.S. company. In KDCE case, the offshore company was Higoal Developments Ltd., which was the parent company of Kid Castle Internet Technologies Limited and Kid Castle Education Software Development Co. Limited, KDCE’s operating companies that run our English language instruction business. The U.S. or shell company, at the time of the share exchange, was King Ball International Technology Corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Kid Castle used to be a Florida corporation until the company voluntarily dissolved its Florida registration with intention to simultaneously incorporate in Delaware and convert into a Delaware corporation. Although the company immediately finalized its registration effort to convert into a Delaware Corporation, the company’s registered agent who was supposed to submit the registration package to the Delaware Secretary of State for certification, failed to make a timely submission. Later in January 2019, when the company realized that the Delaware incorporation/registration package/process was never submitted to the Delaware Secretary of State nor completed in any other way or form, the Company went ahead and resubmitted the required registration package and was then formally re-incorporated in Delaware and convert into a Delaware corporation. Thus, the company was formally incorporated in Delaware and converted into a Delaware Corporation in January 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The re-incorporation in Delaware, which occurred in January 2019, has placed at risk, voidable and unenforceable, all and any liabilities that may have accrued, including any material agreements the Company may have executed during the period between March 22, 2011 and January 2019. To the best of our knowledge, no such liabilities that were accrued and no material agreement were entered into by the company during the period between March 22, 2011 and January 2019. In addition, there could be penalties or legal liabilities that may have accrued as a result of conducting business from 2011 to 2019 without properly registering with any State. To the best of our knowledge, as at September 7, 2020, no such penalties or liabilities has accrued to the company accrued as a result of conducting business from 2011 to 2019 without properly registering with any State. However, there is no guarantee that such penalties or liabilities would not accrue or arise in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 21, 2019, pursuant to a stock purchase agreement dated October 2, 2019, Cannabinoid Biosciences, Inc., a California corporation, purchased one (<span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pn6n6_c20191021__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zF804ZQU3n76" title="Preferred stock, shares outstanding">1</span>) million shares of its preferred shares (<span id="xdx_901_eus-gaap--PreferredStockConversionBasis_c20191020__20191021__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z2fnajUkp3t5" title="Preferred stock, conversion, description">one preferred share is convertible 1,000 share of common stocks</span>) of the Company, representing <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20191021__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember_zI2MzlK8aDXj" title="Ownership percentage">97.82</span>% of our total issued and outstanding voting shares of common stock and preferred stock. Simultaneously with the purchase, the officers and directors of the Company resigned. Frank I Igwealor, Chairman and CEO, Secretary, Treasurer, and Director; Patience C Ogbozor, Director; and Dr. Solomon SK Mbagwu, MD, Director, were elected to replace them. Following the share sales to Cannabinoid Biosciences, Inc., the purchaser converted <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20191020__20191021__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zDaO2Cuxbnqb" title="Conversion of stock, shares converted">900,000</span> of the preferred shares for <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_pid_c20191020__20191021__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zAfJ0uS3Ta99" title="Conversion of stock, shares issued">900,000,000</span> shares of the Company’s current outstanding shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the consummation of the October 21, 2019 transactions, the Company decided to restart filing important information immediately. The Company used the Form 10-12(g) to register its common stock with the SEC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 15, 2020, Kid Castle Educational Corporation (the “Company”) entered into a stock purchase agreement with certain corporation related to our President and CEO with respect to the private placement of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20200914__20200915__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxddB9mDZ9r3" title="Number of shares issued">900,000</span> shares of its preferred stock at a purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pp0p0_c20200914__20200915__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zW9t7oXZhKWd" title="Number of shares issued, value">3</span> in cash and a transfer of <span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20200914__20200915__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_za1MaGUM70Ai" title="Percentage after sale transaction">100</span>% interest in, and control of Community Economic Development Capital, LLC (a California Limited Liability Company). The shares were issued to the investors without registration under the Securities Act of 1933 based upon exemptions from registration provided under Section 4(2) of the Act and Regulation D promulgated thereunder. The issuance did not involve any public offering; no general solicitation or general advertising was used in connection with the offering. Community Economic Development Capital, is a specialty real estate holding company for specialized assets including, affordable housing, opportunity zones properties, medical real estate investments, related commercial facilities, industrial and commercial real estate, and other real estate related services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similarly, on September 16, 2020, as part of its purchase of unregistered securities from certain corporation related to our President and CEO, the Company, received $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pp0p0_c20200914__20200916__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnregisteredSecuritiesMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zsHRhbdkwOn5" title="Number of shares issued, value">3.00</span> in cash and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_pid_c20200914__20200916__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnregisteredSecuritiesMember_zL8DkeK38XAk" title="Number of shares issued">1,000,000</span> shares of its preferred stock, and in exchange transferred <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200916__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CommunityEconomicDevelopmentCapitalLLCMember_zhM3Y52fjBib" title="Ownership percentage">100</span>% interest in, and control of Community Economic Development Capital, LLC (“CED Capital”), a California Limited Liability Company, and <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200916__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember_zfilDRQfKFja">97</span>% of the issued and outstanding shares of Cannabinoid Biosciences, Inc. (“CBDX”), to GiveMePower Corporation, a Nevada corporation. This transaction gave the Company <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200916__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GiveMePowerCorporationMember_zIAa4aqcqrC8" title="Ownership percentage">88</span>% of the voting control of GiveMePower.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 21, 2021, the Company sold Cannabinoid Biosciences, Inc. (“CBDX”), a California corporation, to Premier Information Management, Inc. for $<span id="xdx_904_eus-gaap--ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_pp0p0_c20210420__20210421__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CannabinoidBiosciencesIncMember_zRLjX2nAkrw6" title="Proceeds from sale of subsidiaries">1</span> in cash. As further consideration pursuant to the stated sales, CBDX returned Kid Castle Educational Inc., the parent Company of GMPW, the <span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210420__20210421__srt--ConsolidatedEntitiesAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z3Q8Iw533k33" title="Shares returned during period, shares">100,000</span> shares of KDCE preferred stock and <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20210420__20210421__srt--ConsolidatedEntitiesAxis__custom--CannabinoidBiosciencesIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zjj3RawqWTz1" title="Shares returned during period, shares">900,000,000</span> shares of KDCE common stock that CBDX bought in October of 2019. Pursuant to the April 21, 2021 transaction, CBDX ceased from being a subsidiary of GMPW, effective April 1, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2021, in exchange for its <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211230__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--GiveMePowerCorporationMember_zJ6BJlA1cdO6" title="Ownership percentage">87</span>% control block in GiveMePower Corporation, the Company received <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211230__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlpharidgeCapitalLLCMember_zAEyRtMAXy37" title="Ownership percentage">100</span>% stake in Alpharidge Capital LLC from GiveMePower, in a cashless transaction, resulting in each public company going its separate way as an independent company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements of the Company therefore include the 12 months operating results of the all wholly owned subsidiaries of Alpharidge Capital LLC. (“Alpharidge”), and the balance sheet represent the financial position as at 12/31/2022 of the Company which excludes GiveMePower and its subsidiaries, but Alpharidge Capital LLC and Others subsidiaries in which Kid Castle has a controlling voting interest and entities consolidated under the variable interest entities (“VIE”) provisions of ASC 810, “Consolidation” (“ASC 810”), after elimination of intercompany transactions and accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its subsidiaries, in which the Company has a controlling voting interest and entities consolidated under the variable interest entities (“VIE”) provisions of ASC 810, “Consolidation” (“ASC 810”). Inter-company balances and transactions have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 810 requires that the investor with the controlling financial interest should consolidate the investee/affiliate. ASC 810-10 requires that an equity interest investor consolidates a VIE when it retains an investment in the entity, is considered a variable interest investor in the entity, and is the primary beneficiary of the entity. An investor in a VIE is a “variable interest beneficiary” when, per an arrangement’s governing documents, the investor will absorb a portion of the VIE’s expected losses or will receive a portion of the entity’s “residual returns.” The variable interest beneficiary retaining a controlling financial interest in the VIE is designated as its “primary beneficiary” and must consolidate the VIE. A variable interest beneficiary retains a “controlling financial interest” in a VIE when that beneficiary retains the power to direct the activities of the VIE that have the greatest influence over the VIE’s economic performance and retains an obligation to absorb the VIE’s significant losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380932	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4361021	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zJudWFL1asjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zIUsgxvOoika">Use of Estimates and Assumptions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Cash	19058	usd
CY2022Q4	us-gaap	Cash Cash	64434	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	110000	usd
CY2023Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	380932	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	113	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	798	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zXPtBr4J14Y1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zFaocgPSeoAf">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. The Company maintains cash balances at financial institutions within the United States which are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to limits of approximately $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zyuNItJ0HQYj" title="Cash FDIC insured amount">250,000</span>. The Company has not experienced any losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash bank accounts. It is possible that at times, the company’s cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. In such situation, the Company’s management would assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures would be addressed and mitigated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	0	usd
CY2023Q1	KDCE	Line Of Credit Related Party LineOfCreditRelatedParty	467604	usd
CY2022Q4	KDCE	Line Of Credit Related Party LineOfCreditRelatedParty	419979	usd
CY2023Q1	KDCE	Longterm Line Of Credit Related Party LongtermLineOfCreditRelatedParty	467604	usd
CY2022Q4	KDCE	Longterm Line Of Credit Related Party LongtermLineOfCreditRelatedParty	419979	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	282196	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	599264	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	282196	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	599264	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22324706	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22324706	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.0126
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.0268
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-915814	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-975076	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2023Q1	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-218051	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-232161	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005	pure
CY2023Q1	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	21805	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	23216	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.255	pure
CY2023Q1	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1112060	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1184020	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4361021	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4643217	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1133865	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1207236	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1133865	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1207236	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1133865	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1207236	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1133865	usd
CY2023Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	73371	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1207236	usd
CY2023Q1	us-gaap	Other Operating Income OtherOperatingIncome	380932	usd
CY2023Q1	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2022Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4361021	usd
CY2023Q1	KDCE	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2023Q1	us-gaap	Inventory Real Estate InventoryRealEstate	0.00	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	110000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1316434	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	100000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22324706	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22324706	shares
CY2023Q1	KDCE	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	KDCE	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares

Files In Submission

Name	View Source	Status
0001493152-23-018079-index-headers.html	Edgar Link	pending
0001493152-23-018079-index.html	Edgar Link	pending
0001493152-23-018079.txt	Edgar Link	pending
0001493152-23-018079-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
kdce-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
kdce-20230331_cal.xml	Edgar Link	unprocessable
kdce-20230331_pre.xml	Edgar Link	unprocessable
kdce-20230331_def.xml	Edgar Link	unprocessable
kdce-20230331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KDCE
KID CASTLE EDUCATIONAL CORP Stock $kdce

2023 Q1 Form 10-Q Financial Statement

#000149315223018079 Filed on May 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KDCE KID CASTLE EDUCATIONAL CORP Stock $kdce

2023 Q1 Form 10-Q Financial Statement

#000149315223018079 Filed on May 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KDCE
KID CASTLE EDUCATIONAL CORP Stock $kdce